4 - Azitra, Inc. (0001701478) (Issuer)

BRANFORD, Conn., Feb. 4, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement with certain institutional investor(s) to purchase 3,339,300 shares of common stock at an offering price of $0.2785 per share, in a registered direct offering. The gross proceeds for the offering are expected to be approximately $930.0 thousand before deducting placement agent fees and other offering expenses. This offering is expected to close on February 5, 2025, subject to customary closing conditions. Azitra intends to use the net pro

BRANFORD, Conn., Feb. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at the BIO CEO & Investor Conference being held February 10-11, 2025, in New York City. Details of the presentation are as follows: Event: BIO CEO & Investor Conference Date and Time:  February 10, 2025, at 3:45 p.m. ET Location: The New York Marriott Marquis, Royale Room Presenter: Travis Whitfill, Chief Operating Officer Registration: Link   During the

BRANFORD, Conn., Jan. 27, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, NJ. Details of the presentation are as follows: Event: The Microcap Conference Date and Time:  January 29, 2025, at 11:00 a.m., ET Location: Borgata Hotel Casino & Spa, Studio C, Atlantic City, NJ Presenter: Francisco Salva, Chief Executive Officer During the conference, m

BRANFORD, Conn., Jan. 15, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of its previously announced public offering of 4,857,780 shares of common stock at a public offering price of $0.30 per share. The gross proceeds for the offering are expected to be approximately $1.5 million before deducting placement agent fees and other offering expenses. This offering is expected to close on January 16, 2025, subject to customary closing conditions. Azitra intends to use the net proceeds of this offering for working capital and general corporate purposes.

BRANFORD, Conn., Jan. 14, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has commenced a public offering of shares of its common stock (or pre-funded warrants in lieu thereof). All of the shares of common stock (or pre-funded warrants in lieu thereof) to be sold in the proposed offering will be sold by Azitra. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BRANFORD, Conn., Dec. 20, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the company will present at Biotech Showcase 2025 being held January 13-15, 2025 in San Francisco. Details of the presentation are as follows: Event: Biotech Showcase 2025 Date and Time:  January 13, 2025 at 3:00 p.m., PT Location: Hilton San Francisco Union Square (Yosemite C) Participant: Travis Whitfill, Chief Operating Officer Registration: Link   During the conference, memb

BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company will present at BIO-Europe 2024 in Stockholm, Sweden on Monday, November 4, 2024 at 2:30pm CET (8:30am ET). The corporate update will highlight Azitra's updates and progress on its pipeline, including ATR-12 in development for Netherton syndrome and ATR-04 in development for epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity. Details of the presentation are as follows: BIO-Europe – November 4-6, 2024 Format: Corporate presentation Date/Time: Monday, November 4, 2024, 2:30pm CET (8:30am ET) Par

Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, starting Tuesday, October 15, 2024, at 9:00 a.m. E.T. 2024 Maxim Healthcare Virtual Summit – October 15-17, 2024 Format: Panel presentation Date/Time: Thursday, October 17, 2024 at 2:00 p.m. ET Participant: Travis Whitfill, Chief Operating Officer Location: Virtual Registration: Here Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology compani

Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the upcoming late-breaking presentation related to ATR-04. The presentation by Dr. Mary Spellman will take place on Thursday, September 26, 2024, in a late-breaking oral session entitled "Development of a Staphylococcus epidermidis strain for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity" at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam. ATR-04 is a live biotherapeutic product candidate consisting of an S. epidermidis strain that was isolated fro

SC 13G/A - Azitra, Inc. (0001701478) (Subject)

SC 13G/A - Azitra, Inc. (0001701478) (Subject)

SC 13G/A - Azitra, Inc. (0001701478) (Subject)

SC 13D/A - Azitra, Inc. (0001701478) (Subject)

SC 13G - Azitra, Inc. (0001701478) (Subject)

SC 13G - Azitra, Inc. (0001701478) (Subject)

SC 13G - Azitra, Inc. (0001701478) (Subject)

SC 13G/A - Azitra, Inc. (0001701478) (Subject)

SC 13G - Azitra, Inc. (0001701478) (Subject)

BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

4 - Azitra, Inc. (0001701478) (Issuer)